Clinical evaluation of levofloxacin in complicated urinary tract infection. Study on the recurrence and the susceptibility of urinary isolates to levofloxacin.
|
Accession number;00A0221183
|
| Title;Clinical evaluation of levofloxacin in complicated urinary tract infection. Study on the recurrence and the susceptibility of urinary isolates to levofloxacin. |
| Author;
FUJITA KAZUHIKO
(Juntendo Univ., Sch. of Med.)
FUJIME MAKOTO
(Juntendo Univ., Sch. of Med.)
KAWACHI YOSHIO
(Juntendo Univ., Urayasu Hosp.)
MOROZUMI MAKOTO
(Koshigaya Munic. Hosp.)
TANAKA TOORU
(Koto Hosp.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.1;PAGE.68-74(2000)
|
| Figure&Table&Reference;FIG.3, TBL.9, REF.10 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The therapeutic efficacy of levofloxacin(LVFX) was evaluated in the patients with complicated urinary tract infections(UTI). The patients were orally administered 100mg of LVFX t.i.d. for 7 days. Some patients with severe symptoms or refractory UTI were orally administered 200mg of LVFX t.i.d. for 7 days. The therapeutic efficacy rate was found to be 77.5% in 71 cases which satisfied the criteria of the Japanese UTI committee (4th edition). Recurrence was determined 2 weeks after the completion of the treatment. Clinical symptoms appeared in 29.2% of the cases, and bacteriuria (.GEQ.104/mL) was observed in 57.9% of the cases. Enterococcus faecalis and Escherichia coli were the dominant bacteria in 125 urinary isolates before the treatment. The rate of bacterial eradication was 89.6% at the completion of the treatment. Six strains of Enterococcus faecalis, 2 of CNS, 1 of Staphylococcus epidermidis, 1 of Citrobacter freundii, and 3 of Pseudomonas aeruginosa were not eradicated by the treatment. Staphylococcus species and Candida species frequently emerged at the completion of the treatment. Gram-positive bacteria, such as Enterococcus and Staphylococcus species were frequently isolated at the recurrence. Decreased susceptibility to LVFX was observed in Staphylococcus species isolated at the completion of treatments or at recurrence, however, the susceptibility of other bacteria to LVFX did not change. We conclude that LVFX is an effective agent for the treatment of complicated UTI. However, the high incidence of bacterial recurrence by Gram-positive bacteria should be noted. (author abst.) |
|
|
|
Related Articles;
|
|
